KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing.

Elisabet Zapatero-Solana, Yan Ding, Nicholas Pulliam, Alfonso de Dios, Maria Jesus Ortiz-Ruiz, María José Lallena

Int J Mol Sci 26(6) 2643

PMID40141282
PMCIDPMC11942273
DOI10.3390/ijms26062643
发表日期2025-03-27
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:已完成可用 Figure 的视觉复核,未识别到合格 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:非 KM 图;Figure 4:非 KM 图;Figure 5:非 KM 图。
摘要

摘要

BACKGROUND: CDK4/6 inhibitors (CDK4/6i) combined with hormone therapies have demonstrated clinical benefit in HR+, HER2- breast cancer patients. However, the onset of resistance remains a concern and highlights a need for therapeutic strategies to improve outcomes. The objective of this study was to develop an in vitro model to better understand the mechanisms of resistance to CDK4/6i + hormone therapies and identify therapeutic strategies with potential to overcome this resistance. METHODS: The HR+, HER2- T47D breast cancer cell line genetically modified with a Geminin-Venus reporter construct was treated with CDK4/6i (abemaciclib or palbociclib) in combination with 4-hydroxytamoxifen (tamoxifen). Resistant cells were identified by cell sorting for Geminin (%GEM+), a marker of the S/G2/M phases of the cell cycle, and confirmed by treatment with tamoxifen plus the CDK4/6i used to drive resistance. In resistant cells, following treatment with CDK4/6i + ET (tamoxifen or fulvestrant), the effects on cell proliferation (%GEM+) and viability, gene expression, and protein analysis to evaluate CDK4/6-cyclin D complex composition were examined. RESULTS: Palbociclib + tamoxifen-resistant (PTxR) cells treated with abemaciclib + ET showed decreased %GEM+, %Ki67, and colony formation ability, compared to abemaciclib + tamoxifen-resistant (ATxR) cells treated with palbociclib + ET. Additionally, PTxR cells showed increased CDK4-p21 interaction, compared to ATxR. The CDK6 levels were greater in ATxR cells compared to PTxR cells, associated with CDK4/6i resistance. Additionally, abemaciclib + fulvestrant continued to robustly decrease pRb levels in PTxR models compared to palbociclib + fulvestrant in ATxR models. Transcriptome analysis revealed a depression of the cell cycle and E2F- and Rb-related genes in PTxR cells following treatment with abemaciclib + ET, not present in ATxR cells treated with palbociclib + ET. Both resistant models showed increased EGFR-related gene expression. CONCLUSION: Taken together, we describe CDK4/6i-dependent mechanisms resulting in early-onset resistance to CDK4/6i + ET, using clinically relevant drug concentrations, in preclinical breast cancer cell models. The characterization of these preclinical models post progression on CDK4/6 inhibitor + ET treatment highlights the potential that the specific sequencing of CDK4/6 inhibitors could offer to overcome acquired resistance to CDK4/6i + ET. Abemaciclib + fulvestrant is currently under clinical investigation in patients with HR+, HER2- breast cancer and progression on prior CDK4/6i + ET (NCT05169567, postMONARCH).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Sequential treatments in T47D GEM+ PTxR and T47D GEM+ ATxR cells (2nd treatment). ( A ) GEM+% and ( B ) Ki67% were measured in parallel to validate Geminin as an alternative proliferation marker to the standard Ki67 to assess the proliferating fraction of a cell population (n = 3, two-tailed, unpaired Student’s t -test to resistant control line). ( C ) Colony formation assay in T47D GEM+ PTxR and T47D GEM+ ATxR cell lines. In total, 10,000 cells/well were seeded and cultivated in the presence of the secondary treatments, as well as vehicle control (DMSO/methanol) for 14 days. Colonies were fixed using 100% methanol for 5 min RT and stained with 0.1% crystal violet for 1–2 min. Colony area was quantified with Image J (n = 3, two-tailed, unpaired Student’s t -test to resistant control line). Representative image is shown for n = 3. * p < 0.05, *** p < 0.001.
非 KM Figure
Figure 2Biomarker evaluation in resistant cell lines. ( A ) Biomarker modulation and ( B ) % inhibition were measured to examine whether the lack of sensitivity of ATxR cells to palbociclib was due to the level of biomarker modulation. Efficacy of CDK4/6 inhibitors was measured in a dose–response assay with a fixed concentration of fulvestrant (data are shown as the average of two biological replicates). % Inhibition was calculated as 100—normalized GEM+ treated cells to vehicle. Protein normalization assay was used to demonstrate robust protein content across all samples.
非 KM Figure
Figure 3Co-immunoprecipitation (Co-IP) and Jess immunoblot analysis of p21/p27–cyclin D1–CDK4, p21/p27–cyclin D1–CDK6, and p21/p27–cyclin D1–CDK2 complexes in resistant lines. Fresh protein lysates of PTxR and ATxR cells were immunoprecipitated with either anti-CDK4, anti-CDK6, or anti-CDK2 antibodies and immunoblotted with anti-cyclin D1, p21, and p27 by Jess. Quantification of total peak area to determine levels of protein and Western blot-like images are shown. Data are represented as the average of two biological replicates. The control was normal rabbit serum.
非 KM Figure
Figure 4Pathway analysis for RNAseq data from T47D GEM+ PTxR and ATxR cell lines upon treatment switch. RNAseq was performed on an Illumina NovaSeq 6000 using the Illumina TruSeq Stranded mRNA Library Prep Kit. The gene set (pathway) definitions were either generated from the KEGG official website or downloaded from the Molecular Signature Database. Parameter gene set enrichment analysis (PGSEA) 2 was used to generate enrichment scores for each pathway within each sample using the vehicle control cell lines (for ATxR cell line using abemaciclib/Tx treatment; for PTxR cell line using palbociclib/Tx treatment) as references. A moderated t -statistic implemented in the limma package was used to identify gene set enrichment scores that could discriminate between groups. ( A ) An increase in tamoxifen and ET resistance signatures demonstrates ET resistance for both cell lines. ( B ) Main pathways altered upon treatment switch based on logFC and log p -value. ( C ) Box plot representing main proliferation-related signatures (MoA-related) in the different treatment switches, and androgen response was found to be a potential tumor suppressor (n = 3).
非 KM Figure
Figure 5Analyses of the protein levels of ER, pRb Ser780, Rb, CDK4, CDK6, CDK2, cyclin D1, and cyclin A1/2 1 in resistant PTxR and ATxR cell lines and drug switches. ( A ) Western blot-like images of cell cycle marker panel and ( B ) quantification of total peak area to determine changes in target protein expression, represented as % control calculated with T47D Geminin parental cell line treated with DMSO/methanol (n = 3, two-tailed, unpaired Student’s t -test to vehicle control). Due to the modulation of standard housekeeping proteins (tubulin and vinculin) by the different treatments used, a protein normalization assay was used to demonstrate robust protein content across all samples. * p < 0.05, ** p < 0.01, *** p < 0.001.
非 KM Figure